Mesoblast Limited

Australian regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful results from the first five patients who underwent bone marrow transplantation with haematopoietic stem and progenitor cells expanded by the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs).

The Australian share market showed a quiet response to the federal budget and closed in thin trading on Wednesday. Meanwhile, a growing list of companies seeking capital raising also absorbed attention from investors. The benchmark S&P/ASX200 index fell 21.1 points, or 0.54 per cent, at 3856.1, while the broader All Ordinaries index dropped 21.1 points, or 0.55 per cent, to 3842.5.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced positive three-month interim efficacy results from the first 20 patients enrolled in the Phase 2 heart failure trial of the proprietary allogeneic, or "off-the-shelf", adult stem cell product Revascor(TM).

To ensure that you remain well informed of our remarkable progress, as your Chairman, I will be providing you with regular updates outlining Mesoblast's key near-term objectives and major highlights. Following our first quarter results, I thought it opportune to provide you with my first of planned regular communications.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB(PINK:MBLTY), today announced it has received approval at Melbourne's Epworth hospital to commence a Phase 2 trial of its allogeneic, or "off-the-shelf", cell therapy product for fusion of the cervical spine.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) has announced the successful closure of the equity raising that forms the funding package for the expansion of MSB's clinical programs focusing on bone and cartilage regenerative programs for spinal vertebral disc disease.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) Australia's regenerative medicine company, today announced that it has successfully completed a private placement to existing, as well as new, institutional and sophisticated investors, raising A$10.81 million.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) Australia's regenerative medicine company today announced that three separate papers disclosing clinical and preclinical trial results were presented this week to orthopaedic specialists attending the 55th annual meeting of the American Academy of Orthopedic Surgeons (AAOS) and the Orthopedic Research Society (ORS). The meetings, underway in Las Vegas, attract an estimated 15,000 orthopedic healthcare professionals from around the world.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced its half-yearly results.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful achievement of the key safety milestone in the first low-dose cohort of patients treated with Revascor(tm), the proprietary allogeneic, or "off-the-shelf", universal adult stem cell product for congestive heart failure.